Aggressive locoregional management of recurrent peritoneal sarcomatosis

Baumgartner, Joel M.; Ahrendt, Steven A.; Pingpank, James F.; Holtzman, Matthew P.; Ramalingam, Lekshmi; Jones, Heather L.; Zureikat, Amer H.; Zeh, Herbert J.; Bartlett, David L.; Choudry, Haroon A.

doi:10.1002/jso.23232

Cited by 29 publications

(28 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Likewise, published data in children with isolated peritoneal sarcomatosis also revealed significant survival benefit for patients who were able to undergo a complete cytoreduction and intraperitoneal chemotherapy [14]. Similar data have also been observed in adults with isolated peritoneal sarcomatosis although samples sizes in various trials have been small [15, 16]. However, the number of patients who achieve long term benefit from this approach is limited and in most diseases the availability of randomized clinical trial data is scarce.…”

Section: Introductionmentioning

confidence: 69%

Autophagy Induction Results in Enhanced Anoikis Resistance in Models of Peritoneal Disease

Chen

David

Cook-Spaeth

et al. 2017

Molecular Cancer Research

View full text Add to dashboard Cite

Peritoneal carcinomatosis and peritoneal sarcomatosis (PC/PS) is a potential complication of nearly all solid tumors and results in profoundly increased morbidity and mortality. Despite the ubiquity of PC/PS, there are no clinically relevant targeted therapies for either its treatment or prevention. To identify potential therapies, we developed in vitro models of PC/PS using tumor cell lines and patient-derived spheroids (PDS) that recapitulate anoikis resistance and spheroid proliferation across multiple cancer types. Epithelial- and mesenchymal-derived cancer cell lines (YOU, PANC1, HEYA8, CHLA10, TC71) were used to generate spheroids and establish growth characteristics. Differential gene expression analyses of these spheroids to matched adherent cells, revealed a consensus spheroid signature. This spheroid signature discriminates primary tumor specimens from tumor cells found in ascites of ovarian cancer patients and in our PDS models. Key in this gene expression signature is BNIP3 and BNIP3L, known regulators of autophagy and apoptosis. Elevated BNIP3 mRNA expression is associated with poor survival in ovarian cancer patients and elevated BNIP3 protein, as measured by immunohistochemistry (IHC), is also associated with higher-grade tumors and shorter survival. Pharmacological induction of autophagy with rapamycin significantly increased spheroid formation and survival while decreasing the induction of apoptosis. In contrast, the autophagy inhibitor hydroxychloroquine abrogated spheroid formation with a clear increase in apoptosis. Modulation of BNIP3 and the critical autophagy gene Beclin-1 (BECN1) also caused a significant decrease in spheroid formation. Combined, these data demonstrate how modulation of BNIP3-related autophagy, in patient-derived spheroids and in vitro spheroid models, alters the survival and morphology of spheroids.

show abstract

Section: Introductionmentioning

confidence: 69%

Autophagy Induction Results in Enhanced Anoikis Resistance in Models of Peritoneal Disease

Chen

David

Cook-Spaeth

et al. 2017

Molecular Cancer Research

View full text Add to dashboard Cite

show abstract

“…There are few series that report the use of cytoreduction with or without intraperitoneal chemotherapy in the management of recurrent RPLPS. Most studies include multiple sarcoma histologic subtypes such as liposarcoma and gastrointestinal stromal tumor (GIST) . In a study from the Istituto Nazionale Tumori in Milan, 37 patients with sarcomatosis were treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) .…”

Section: Management Of Rplps Recurrencementioning

confidence: 99%

Multiply recurrent retroperitoneal liposarcoma

Bagaria

Gabriel

Mann³

2017

Journal of Surgical Oncology

View full text Add to dashboard Cite

Retroperitoneal liposarcomas (RPLPS) are rare tumors that represent at least 50% of all retroperitoneal sarcomas. Surgical resection remains the standard of care. Unfortunately, many RPLPS patients will develop a local recurrence and subsequently die in the absence of distant metastasis. This review outlines the factors that predict local recurrence and influence the management of first and subsequent multiply recurrent RPLPS.

show abstract

“…Reported 5‐year OS of 65% and 5‐year PFS of 30% were encouraging, suggesting that CRS/HIPEC might offer the best results in patients with PS from US . Prognostic factors after CRS/HIPEC include the degree of cytoreduction, histopathology/tumor grade, and tumor load, with complete cytoreduction as the most important factor positively affecting overall and progression‐free survival .…”

Section: Discussionmentioning

confidence: 98%

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in seven patients with peritoneal sarcomatosis from uterine sarcoma

Sardi

Muñoz‐Zuluaga

Sittig

et al. 2018

Clinical Case Reports

View full text Add to dashboard Cite

Key Clinical MessagePeritoneal sarcomatosis from uterine sarcoma is a rare disease with no effective treatment and poor prognosis. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has successful results in peritoneal carcinomatosis from gastrointestinal/gynecological origins. We show that CRS/HIPEC is safe, feasible, and may benefit selected patients with peritoneal sarcomatosis from uterine sarcoma.

show abstract

Aggressive locoregional management of recurrent peritoneal sarcomatosis

Abstract: Cytoreduction combined with HIPEC may improve loco-regional disease control in patients with recurrent sarcomatosis.

Cited by 29 publications

References 24 publications

Autophagy Induction Results in Enhanced Anoikis Resistance in Models of Peritoneal Disease

Autophagy Induction Results in Enhanced Anoikis Resistance in Models of Peritoneal Disease

Multiply recurrent retroperitoneal liposarcoma

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in seven patients with peritoneal sarcomatosis from uterine sarcoma

Contact Info

Product

Resources

About